The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
|Articles|March 2, 2015
- Pharmaceutical Technology-03-02-2015
- Volume 39
- Issue 3
Pharmaceutical Technology, March 2015 Issue (PDF)
Click the title above to open the Pharmaceutical Technology March 2015 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 11 years ago
Vaccine Development and Production Challenges Manufacturersover 11 years ago
Europe Strives for a More Efficient Generic-Drug Approval Frameworkover 11 years ago
Kason Offers Screen Replacementover 11 years ago
GEA Homogenizer Offers Scalabilityover 11 years ago
PolyScience Chiller and Circulator Enhances Temperature Controlover 11 years ago
Ross Control System Increases Consistencyover 11 years ago
Industry Expert Q&A with Richard Grantover 11 years ago
Managing Supplier Data Collectionover 11 years ago
The Global Biomanufacturing Outsourcing Marketover 11 years ago
Lyophilization Cycle Optimization of Cell-Derived ProductsAdvertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
PharmTech Weekly Roundup—September 18, 2026
4
CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up
5